Прогностическое Значение Клинико-Патогенетических Особенностей Развития Хронической Болезни Почек Вследствие Гломерулярных Заболеваний
Abstract
В статье изложены данные об этиологии и патогенезе хронической болезни почек вследствие гломерулярных заболеваний. Гломерулопатии представляют собой заболевания почек, при которых происходит поражение структуры и функции клубочков. Первичные гломерулопатии включают воспалительные гломерулярные заболевания (гломерулонефриты) и невоспалительные гломерулопатии
References
Vleming LJ, Bruijn JA, van Es LA. The pathogenesis ofprogressive renal failure. Neth J Med 1999;54:114–128
Eddy AA. Experimental insights into the tubulointerstitialdisease accompanying primary glomerular lesions. J Am SocNephrol 1994;5:1273–1277
Ichikawi I, Harris RC. Angiotensin actions in the kidney:renewed insight into the old hormone. Kidney Int 1991;40:583–596
Orphanides C, Fine LG, Norman JT. Hypoxia stimulatesproximal tubular cell matrix production via a TGF-beta1-independent mechanism. Kidney Int 1997;52:637–647
López-Novoa JM, Nieto MA. Inflammation and EMT: analliance towards organ fibrosis and cancer progression. EMBOMol Med 2009;1:303–314
Couser WG. Pathogenesis of glomerular damage inglomerulonephritis. Nephrol Dial Transplant 1998;13:10–15
Isaka Y, Akagi Y, Ando Y, et al. Cytokines andglomerulosclerosis. Nephrol Dial Transplant 1999;14:30–32
Couser W G. Complement inhibitors andglomerulonephritis: are we there yet? J Am Soc Nephrol2003;14:815–818
Cunard R, Jelly CJ. Immune-mediated renal disease. JAllergy Clin Immunol 2003;111:S637–644
Shimizu A, Masuda Y, Kitamura H, et al. Recovery ofdamaged glomerular capillary network with endothelial cellapoptosis in experimental proliferative glomerulonephritis.Nephron 1998;79:206–214
U.S. Renal Data System, USRDS 2005 Annual Data 35ISSN 15616274. Нефрология. 2013. Том 17. №2.Report: Atlas of End-Stage Renal Disease in the United States,National Institutes of Health, National Institute of Diabetes andDigestive and Kidney Diseases, Bethesda, MD, 2005
López-Hernández FJ, López-Novoa JM. The lord of thering: Mandatory role of the kidney in drug therapy of hypertension.Pharmacol Ther 2006;111:53–80
López-Novoa JM, Martínez-Salgado C, Rodríguez-PeñaAB, et al. Common pathophysiological mechanisms of chronickidney disease: Therapeutic perspectives. Pharmacol Ther2010;128:61–81
Wesson LG. Physical factors and glomerulosclerosis.Cause or coincidence? Nephron 1998;78:125–130
Wiggins RC. The spectrum of podocytopathies: a unifyingview of glomerular diseases. Kidney Int 2007;71:1205–1214147. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathyand proteinuria in diabetic glomerulopathy. Curr Diabetes Rev2008;4:39–45
Moreno JA, Sanchez-Niño MD, Sanz AB, et al. A slit inpodocyte death. Curr Med Chem 2008;15:1645–1654
Kang YS, Li Y, Dai C, et al. Inhibition of integrin-linkedkinase blocks podocyte epithelial-mesenchymal transition andameliorates proteinuria. Kidney Int 2010;78:363–373
Kriz W, LeHir M. Pathways to nephron loss starting fromglomerular diseases-insights from animal models. Kidney Int2005;67:404–419
Harris RC, Akai Y, Yasuda T, et al. The role of physicalforces in alterations of mesangial cell function. Kidney Int 1994;45[Suppl]: S17–S21
Funabiki K, Horikoshi S, Tomino Y, et al.Immunohistochemical analysis of extracellular components inthe glomerular sclerosis of patients with glomerulonephritis. ClinNephrol 1990;34:239–246
Makino H, Kashihara N, Sugiyama H, et al. Role ofapoptosis in the progression of glomerulosclerosis. ContribNephrol 1996;118:41–47
Kurogi Y. Mesangial cell proliferation inhibitors forthe treatment of proliferative glomerular disease. Med Res Rev2003;23:15–31
Morel-Maroger Striker L, Killen PD, Chi E, et al. Thecomposition of glomerulosclerosis. I. Studies in focal sclerosis,crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest 1984;51:181–192
Floege J, Johnson RJ, Couser WG. Mesangial cells in thepathogenesis of progressive glomerular disease in animal models.Clin Investig 1992;70:857–864
Massy ZA, Guijarro C, O’Donnell MP, et al. The centralrole of nuclear factor-kappa B in mesangial cell activation. KidneyInt 1999;71 [Suppl]: S76–S79
Johnson RJ, Alpers CE, Yoshimura A, et al. Renalinjury from angiotensin II-mediated hypertension. Hypertension1992;19:464–474
Ardaillou R, Chansel D, Chatziantoniou C, et al.Mesangial AT1 receptors: expression, signaling, and regulation.J Am Soc Nephrol 1999;10:S40–46
Kagami S, Kondo S, Löster K, et al. Alpha1beta1integrin-mediated collagen matrix remodeling by rat mesangialcells is differentially regulated by transforming growth factorbeta and platelet-derived growth factor-BB. J Am Soc Nephrol1999;10:779–789
Haberstroh U, Zahner G, Disser M, et al. TGF-betastimulates rat mesangial cell proliferation in culture: role of PDGFbeta-receptor expression. Am J Physiol 1993;264:F199–205
Bessho K, Mizuno S, Matsumoto K, et al. Counteractiveeffects of HGF on PDGF-induced mesangial cell proliferation ina rat model of glomerulonephritis. Am J Physiol Renal Physiol2003;284:F1171–180
Gomez-Garre D, Ruiz-Ortega M, Ortego M, et al. Effectsand interactions of endothelin-1 and angiotensin II on matrix proteinexpression and synthesis and mesangial cell growth. Hypertension1996;27:885–892
Hahn S, Krieg RJ Jr, Hisano S, et al. Vitamin E suppressesoxidative stress and glomerulosclerosis in rat remnant kidney.Pediatr Nephrol 1999;13:195–198
Jaimes EA, Galceran JM, Raij L. Angiotensin II inducessuperoxide anion production by mesangial cells. Kidney Int1998;54:775–784
Couser WG. Pathogenesis of glomerulonephritis. KidneyInt 1993;42 [Suppl]: S19–S26
Grande MT, Perez-Barriocanal F, Lopez-Novoa JM.Role of inflammation in túbulo-interstitial damage associated toobstructive nephropathy. J Inflamm (Lond) 2010;7:19
Johnson RJ, Iida H, Alpers CE, et al. Expression ofsmooth muscle cell phenotype by rat mesangial cells in immunecomplex nephritis. Alpha-smooth muscle actin is a marker ofmesangial cell proliferation. J Clin Invest 1991;87:847–858
Alpers CE, Hudkins KL, Gown AM, et al. Enhancedexpression of ”muscle-specific” actin in glomerulonephritis. KidneyInt 1992;41:1134–1142
Stokes MB, Holler S, Cui Y, et al. Expression of decorin,biglycan, and collagen type I in human renal fibrosing disease.Kidney Int 2000;57:487–498
Couser WG, Johnson RJ. Mechanisms of progressiverenal disease in glomerulonephritis. Am J Kidney Dis 1994;23:193–198
Justo P, Sanz AB, Sanchez-Niño MD, et al. Cytokinecooperation in renal tubular cell injury: the role of TWEAK. KidneyInt 2006;70:1750–1758
Sanchez-Niño MD, Benito-Martin A, Gonçalves S, etal. TNF superfamily: a growing saga of kidney injury modulators.Mediators Inflamm;2010. pii: 182958. Epub 2010 Oct 4
Strutz F, Neilson EG. New insights into mechanisms offibrosis in immune renal injury. Springer Semin Immunopathol2003;24:459–476
Border WA, Noble NA. TGF-beta in kidney fibrosis: atarget for gene therapy. Kidney Int 1997;51:1388–1396
Tamaki K, Okuda S. Role of TGF-beta in the progressionof renal fibrosis. Contrib Nephrol 2003;139:44–65
Chiarugi A. «Simple but not simpler»: toward aunified picture of energy requirements in cell death. FASEB J2005;19:1783–1788
Rusterholz C, Gupta AK, Huppertz B, et al. Solublefactors released by placental villous tissue: Interleukin-1 is apotential mediator of endothelial dysfunction. Am J Obstet Gynecol2005;192:618–624
Zhang C, Wu J, Xu X, et al. Direct relationship betweenlevels of TNF-alpha expression and endothelial dysfunction inreperfusion injury. Basic Res Cardiol 2010;105:453–464
Camussi G, Turello E, Tetta C, et al. Tumor necrosisfactor induces contraction of mesangial cells and alters theircytoskeletons. Kidney Int 1990;38:795–802
López-Novoa JM. Potential role of platelet activatingfactor in acute renal failure. Kidney Int 1999;55:1672–1682
Molitoris BA, Sutton TA. Endothelial injury anddysfunction: role in the extension phase of acute renal failure.Kidney Int 2004;66:496–499
Bonventre JV. Pathophysiology of AKI: injury and normaland abnormal repair. Contrib Nephrol 2010;165:9–17. full_text
Rodriguez-Barbero A, L’Azou B, Cambar J,et al. Potentialuse of isolated glomeruli and cultured mesangial cells as in vitromodels to assess nephrotoxicity. Cell Biol Toxicol 2000;16:145–153 36ISSN 15616274. Нефрология. 2013. Том 17. №2.
Wolf G, Ziyadeh FN. Cellular and molecular mechanismsof proteinuria in diabetic nephropathy. Nephron Physiol2007;106:26–31
Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathyand proteinuria in diabetic glomerulopathy. Curr Diabetes Rev2008;4:39–45
Smeets B, Dijkman H, Wetzels J, et al. Lessons fromstudies on focal segmental glomerulosclerosis: an important rolefor parietal epithelial cells? J Pathol 2006;210:263–272
Asano T, Niimura F, Pastan I, et al. Permanent genetictagging of podocytes: fate of injured podocytes in a mouse modelof glomerular sclerosis. J Am Soc Nephrol 2005;16:2257–2262
Pätäri-Sampo A, Ihalmo P, Holthöfer H. Molecular basis ofthe glomerular filtration: nephrin and the emerging protein complexat the podocyte slit diaphragm. Ann Med 2006;38:483–492
Barisoni L, Mundel P. Podocyte biology and theemerging understanding of podocyte diseases. Am J Nephrol.2003;23:353–360
Remuzzi G, Bertani T. Pathophysiology of progressivenephropathies. N Engl J Med 1998;339:1448–1456
Morioka Y, Koike H, Ikezumi Y, et al. Podocyte injuriesexacerbate mesangial proliferative glomerulonephritis. KidneyInt 2001;60:2192–2204
Sawai K, Mori K, Mukoyama M, et al. Angiogenic proteinCyr61 is expressed by podocytes in anti-Thy-1 glomerulonephritis.J Am Soc Nephrol 2003;14:1154–1163
Chen S, Kasama Y, Lee JS, et al. Podocyte-derivedvascular endothelial growth factor mediates the stimulation ofalpha3(IV) collagen production by transforming growth factorbeta1 in mouse podocytes. Diabetes 2004;53:2939–2949
Kang YS, Park YG, Kim BK, et al. Angiotensin II stimulatesthe synthesis of vascular endothelial growth factor through thep38 mitogen activated protein kinase pathway in cultured mousepodocytes. J Mol Endocrinol 2006;36:377–388
Wang L, Kwak JH, Kim SI, et al. Transforming growthfactor-beta1 stimulates vascular endothelial growth factor 164 viamitogen-activated protein kinase kinase 3-p38alpha and p38deltamitogen-activated protein kinase-dependent pathway in murinemesangial cells. J Biol Chem 2004;279:33213–33219
Kriz W, Gretz N, Lemley KV. Progression of glomerulardiseases: Is the podocyte the culprit? Kidney Int 1998;54:687–697
Pagtalunan ME, Miller PL, Jumping-Eagle S, et al.Podocyte loss and progressive glomerular injury in type II diabetes.J Clin Invest 1997;99:342–348.
Lemley KV, Lafayette RA, Safai M, et al. Podocytopeniaand disease severity in IgA nephropathy. Kidney Int 2002;61:1475–1485
Perico N, Benigni A, Remuzzi G. Present and futuredrug treatments for chronic kidney diseases: evolving targets inrenoprotection. Nat Rev Drug Discov 2008;7:936–953
